Vociprotafib
Targeted therapy of solid tumors carrying MAPK-pathway aberrations
- CAS No.
- 2172652-48-9
- Indication Class
- Oncology / Hematology
- Patent Expiry
- To be assessed
- Therapeutic Area
- Oncology / Targeted Therapy
- Labeled Purity
- 98%+
- Registration Readiness
- GMP/DMF
- Commercialization Tier
- API (Commercialized)
- Linked Intermediates
- Confirm per inquiry
Key Intermediates for This API
Order: listed intermediates that accept enquiries first; fragments shared across several APIs rank higherNo intermediate entries are on file for this API yet. You can still enquire by CAS number — we will route it to the supply side for manual sourcing.
Listing Logic · Why It's Worth Listing
An SHP2 inhibitor confronting KRAS/EGFR resistance, a core combination partner with KRAS inhibitors and EGFR antibodies.
Oncology / Targeted Therapy · Marketed; available for immediate sourcing
GMP/DMF-ready; supports regulatory filing and audit in target markets
Intermediates confirmed per inquiry
Product Description
Vociprotafib is a small molecule anticancer drug currently in development, primarily targeting the selective inhibition of protein tyrosine phosphatase SHP2 (PTPN11).
Supply source: Unibest · Vociprotafib, sourced, vetted and delivered by Unibest. Therapeutic area, indication and listing rationale are qualitative summaries based on public drug knowledge for business reference; actual registration availability and quality specifications are subject to DMF/GMP documentation and the technical agreement confirmed at order.